
(R)-Equol
CAS No. 221054-79-1
(R)-Equol( (+)-Equol )
Catalog No. M26529 CAS No. 221054-79-1
(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 32 | In Stock |
![]() ![]() |
5MG | 51 | In Stock |
![]() ![]() |
10MG | 87 | In Stock |
![]() ![]() |
25MG | 146 | In Stock |
![]() ![]() |
50MG | 214 | In Stock |
![]() ![]() |
100MG | 322 | In Stock |
![]() ![]() |
200MG | 475 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product Name(R)-Equol
-
NoteResearch use only, not for human use.
-
Brief Description(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.
-
Description(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.(In Vitro):(R)-Equol produced a dose-dependent inhibitory effect on the invasive ability of MDA-MB-231 cells, and this inhibitory effect was obvious at the highest test concentration (50 μM).Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035) .(In Vivo):In Animals, (R)-Equol has a significantly reduced number of palpable tumors over time when compared with Controls (P=0.002).In addition, the number of palpable tumors formed by each rat in the (R)-Equol fed group was significantly lower than that of rats treated with S-(-)equol (P = 0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animals is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compared with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003) .
-
In Vitro(R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively. (R)-Equol induces a dose-dependent inhibitory effect on the invasive capacity of MDA-MB-231 cells that is significant at the highest concentration tested (50 μM). Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035).
-
In VivoAnimals fed (R)-Equol have a significantly reduced number of palpable tumors over time when compare with Controls (P=0.002). Furthermore, the number of palpable tumors formed per rat in the (R)-Equol-fed group is significantly lower than that of rats treated with S-(-)equol (P=0.008).(R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animal is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compare with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003).
-
Synonyms(+)-Equol
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptormPGES-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number221054-79-1
-
Formula Weight242.274
-
Molecular FormulaC15H14O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (412.76 mM)
-
SMILESOc1ccc(cc1)[C@@H]1COc2cc(O)ccc2C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Guerrero, M.D., Aquino, M., Bruno, I., et al. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the γ-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. Journal of Medicinal Chemistry 50, 2176-2184 (2007).
molnova catalog



related products
-
Etonogestrel
Etonogestrel is a steroidal progestin used in hormonal contraceptives.
-
Astragaloside IV
Astragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.
-
Thymopentin
Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone.